2021 Fiscal Year Final Research Report
Validation of treatment efficiency by Bacillus Calmette–Guérin (BCG) for cervical intraepithelial neoplasia with aberrant expression of atypical protein kinase C as cell polarity regulator.
| Project/Area Number |
19K18647
|
|---|
| Research Category |
Grant-in-Aid for Early-Career Scientists
|
| Allocation Type | Multi-year Fund |
|---|
| Review Section |
Basic Section 56040:Obstetrics and gynecology-related
|
|---|
| Research Institution | Yokohama City University |
|---|
Principal Investigator |
|
|---|
| Project Period (FY) |
2019-04-01 – 2022-03-31
|
| Keywords | 子宮頸癌 / 子宮頸部上皮内腫瘍 |
|---|
| Outline of Final Research Achievements |
We studied to create new chemotherapy and molecular targeted therapy for cervical cancer and cervical intraepithelial neoplasia. Bacillus Calmette-Guerin (BCG), which is clinically used for bladder cancer treatment, suppressed cell proliferation of cervical cancer cell line. We proved that atypical Protein Kinase C(aPKC), cell polarity regulator, related to cancer cell invasion ability modulated by several genes.
|
| Free Research Field |
婦人科腫瘍
|
| Academic Significance and Societal Importance of the Research Achievements |
CINの標準治療は外科治療であるがBCGによる腫瘍増殖抑制効果が示唆され，今後保存的治療の可能性が期待される．また，子宮頸癌の発がんに対する分子標的治療薬は限られており進行子宮頸がんの予後は依然として不良である．これまでに、細胞極性制御因子であるaPKCの発現異常が病変の進行と関連している可能性が示されていた．本研究によりその機序が浸潤能力の増強であり，介在する複数の遺伝子も明らかとなり，aPKCが分子標的治療の標的分子として有力な候補となった．
|
